"Juniper's proven solutions and capabilities will further support Catalent's strategic goal to be the most comprehensive partner for pharmaceutical innovators." Founded in 1986 as Columbia Laboratories, Juniper was rebranded in 2015—two years after it acquired the Nottingham site established by University of Nottingham spinout Molecular Profiles. Boston-based Juniper has nearly 150 employees with expertise in solid-state and preclinical formulation screening for lead-candidate selection, phase-appropriate dose-form development, and technologies for challenging molecules. Those capabilities, Catalent said, will be strengthened and expanded through integration with its OptiForm ® Solution Suite platform. Juniper also provides bioavailability enhancement solutions for the development of poorly soluble compounds, including nano-milling, spray drying, hot-melt extrusion, lipid-based drug delivery, and cGMP clinical manufacturing, including specialized facilities and controls for potent and controlled substances.